Colgate-Palmolive Company
CL
$87.89
+1.26%
Colgate-Palmolive Company is a global consumer staples manufacturer founded in 1806, producing oral care (its namesake toothpaste and toothbrushes account for over 40% of sales), personal care (shampoos, shower gels, deodorants), home care products, and specialty pet nutrition through its Hill's brand, selling in over 200 countries. The company is a market leader in oral care with dominant global share, and its Hill's pet nutrition business (roughly one-fourth of sales) provides a higher-growth, premium-margin counterweight to its mature core categories. International sales represent about 70% of total business, with nearly half from emerging markets, making the company a leveraged play on global consumer demand and currency movements. The current investor narrative centers on whether Colgate can sustain its recent revenue acceleration — Q1 2026 revenue grew 8.4% year-over-year to $5.32 billion — while navigating a rotation out of defensive staples into more cyclical value names, as reflected in the recent 'sell the leaders, buy the laggards' market commentary and the stock's underperformance versus the S&P 500 over the past year.…
CL
Colgate-Palmolive Company
$87.89
Investment Opinion: Should I buy CL Today?
The synthesized recommendation is Hold, with a bias toward accumulating on weakness for income-oriented investors. The core thesis is that Colgate offers a safe, dividend-paying defensive staple with improving revenue growth, but its premium valuation and recent relative underperformance limit near-term upside. The analyst consensus rating of Buy (mean 2.05) and average target price of $98.95 imply 14.0% upside, but the stock's low beta of 0.323 and 2.85% dividend yield make it more of a income and stability play than a growth engine.
The supporting evidence includes: 1) Revenue growth of 8.41% year-over-year in Q1 2026, a significant acceleration from prior quarters; 2) Gross margin of 60.59%, well above the sector average of 40-50%, demonstrating strong pricing power; 3) Free cash flow of $3.767 billion (TTM) providing a 5.9% FCF yield, which comfortably covers the dividend; and 4) A forward PE of 21.13x, which is a premium to the sector but justified by superior margins and market leadership. The stock's 2.85% dividend yield is competitive, though the 85.5% payout ratio is a concern.
The biggest risks that could invalidate the thesis are: 1) A slowdown in revenue growth if the Q1 acceleration proves temporary, which could lead to multiple compression; 2) Continued rotation out of defensive staples, as highlighted by the recent 'sell the leaders, buy the laggards' market commentary, which could keep the stock range-bound; and 3) Currency headwinds from international operations (70% of sales), which could erode earnings. The rating would upgrade to Buy if the stock pulls back to the $80-82 range (offering a more attractive entry point and dividend yield above 3%), or if revenue growth sustains above 6% for two consecutive quarters. It would downgrade to Sell if revenue growth turns negative or if the payout ratio exceeds 90% without earnings growth. Relative to its history and peers, the stock appears fairly valued to slightly overvalued, with the forward PE near the middle of its five-year range but the trailing PE near the upper end.
Sign up to view all
CL 12-Month Price Forecast
Colgate presents a balanced risk-reward profile with a neutral stance. The company's revenue acceleration to 8.41% YoY in Q1 2026 is encouraging, but the premium forward PE of 21.13x already prices in much of the recovery. The strong free cash flow yield of 5.9% and 2.85% dividend yield offer support, but the high payout ratio of 85.5% limits flexibility. Analyst sentiment is positive with a Buy consensus and 14% upside to the average target, yet the stock's low beta and defensive nature mean it will likely lag in a bull market. The key tension is whether the revenue acceleration is sustainable; if it is, the stock could re-rate toward $99, but if it fades, the downside to the 52-week low of $74.55 is meaningful. I would upgrade to bullish if revenue growth sustains above 6% for two more quarters and margins expand, and downgrade to bearish if growth falls below 3% or the payout ratio exceeds 90%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Colgate-Palmolive Company's 12-month outlook, with a consensus price target around $98.95 and implied upside of +12.6% versus the current price.
Average Target
$98.95
0 analysts
Implied Upside
+12.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$87 - $110
Analyst target range
The stock is covered by 20 analysts, with a consensus recommendation of 'Buy' (recommendation mean of 2.05 on a scale where 1 is Strong Buy and 5 is Strong Sell). The average target price is $98.95, implying approximately 14.0% upside from the current price of $86.80. The consensus leans bullish, supported by recent institutional ratings that show mostly Buy/Overweight actions from firms like Citigroup, Piper Sandler, UBS, RBC Capital, JP Morgan, and Morgan Stanley, with no downgrades observed in the provided data. The estimated EPS average of $4.79 for the forward year provides a fundamental anchor for the bullish case.
The target price range spans from a low of $87.00 to a high of $110.00, a spread of $23.00 or roughly 26% of the average target, indicating moderate uncertainty. The high target of $110 assumes successful execution on revenue acceleration, margin expansion, and possibly multiple expansion as the market rewards defensive growth; the low target of $87 is essentially flat with the current price, implying that even the most cautious analyst sees limited downside, likely pricing in stable earnings but no re-rating. The tight clustering of recent ratings (mostly reiterations rather than upgrades) suggests analysts are in a holding pattern, waiting for evidence that the Q1 2026 revenue acceleration is sustainable before adjusting targets. With the stock trading below the average target and the low target essentially at current levels, the risk-reward skew appears favorable for long-term investors, though the lack of recent upgrades suggests limited near-term catalysts.
Drowning in data?
Find the real signal!
Bulls vs Bears: CL Investment Factors
The bull case rests on Colgate's accelerating revenue growth (8.4% YoY), robust gross margins above 60%, strong free cash flow generation, and a consensus Buy rating with 14% upside to analyst targets. The bear case highlights the stock's significant underperformance versus the S&P 500 (-12.96 percentage points over one year), an elevated payout ratio of 85.5%, high leverage (debt-to-equity of 147.93%), and a premium valuation that assumes continued execution. Currently, the bear evidence appears slightly stronger in the near term, given the persistent rotation out of defensive staples and the stock's negative short-term momentum (-5.98% over one month). The single most important tension is whether the Q1 2026 revenue acceleration is sustainable or merely a temporary pricing/currency tailwind; if it proves durable, the stock could re-rate toward the analyst average target of $98.95, but if it fades, the premium multiple could compress toward the low target of $87.00.
Bullish
- Revenue acceleration to 8.4% YoY: Q1 2026 revenue grew 8.41% year-over-year to $5.324 billion, a sharp acceleration from the roughly 1-3% growth seen in prior quarters. This marks the strongest sequential gain in the past four quarters, suggesting Colgate's pricing power and volume recovery are gaining traction.
- Fortress gross margin above 60%: Gross margin of 60.59% in Q1 2026 remains near the top of its historical 59-61% range, reflecting strong pricing power and brand equity. This margin stability provides a buffer against input cost inflation and supports consistent cash generation.
- Attractive 5.9% free cash flow yield: Trailing twelve-month free cash flow of $3.767 billion on a $63.9 billion market cap yields approximately 5.9%, well above the sector median. This cash flow comfortably covers the $417 million quarterly dividend and $306 million in buybacks, ensuring shareholder returns remain intact.
- Analyst consensus Buy with 14% upside: 20 analysts rate the stock a Buy (mean 2.05) with an average target of $98.95, implying 14.0% upside from the current $86.80. The low target of $87.00 is essentially flat with the current price, suggesting limited downside even in a cautious scenario.
Bearish
- Relative underperformance vs. S&P 500: CL has gained just 3.26% over the past year versus the S&P 500's 16.22%, a relative strength gap of -12.96 percentage points. This underperformance reflects a market rotation away from defensive staples into growth and cyclical names, a trend that may persist.
- Elevated payout ratio limits flexibility: The dividend payout ratio of 85.5% is well above the sector norm of 60-70%, leaving little room for dividend increases without earnings expansion. This constrains management's ability to return additional capital or invest in growth initiatives.
- High leverage and tight liquidity: Debt-to-equity of 147.93% and a current ratio of 0.995 indicate that current liabilities slightly exceed current assets. While free cash flow is strong, the balance sheet carries meaningful financial risk, especially if interest rates remain elevated.
- Earnings volatility from non-operating items: Q4 2025 reported a net loss of $37 million due to a $970 million other-expense charge, highlighting how non-operating items can swing quarterly results. This volatility complicates earnings predictability and may deter some investors.
CL Technical Analysis
Colgate-Palmolive is in a range-bound consolidation phase, with the current price of $86.80 sitting roughly 12.6% below its 52-week high of $99.33 and about 16.4% above its 52-week low of $74.55, placing it at approximately 50% of its 52-week range. The 1-year price change of +3.26% masks significant underperformance versus the S&P 500's +16.22% over the same period, a relative strength gap of -12.96 percentage points that signals the stock has been a laggard in a market favoring growth and cyclical exposure. This mid-range positioning suggests neither a compelling momentum breakout nor a deep-value falling-knife scenario, but rather a stock searching for direction amid a rotation away from defensive staples.
Recent momentum has deteriorated sharply, with the 1-month price change of -5.98% and 3-month change of -2.96% both negative, contrasting with the positive 1-year trend and the +11.73% year-to-date gain. This divergence — positive YTD but negative short-term — indicates the stock has given back a meaningful portion of its early-2026 gains, with the 1-month relative strength versus SPY at -4.92 percentage points. The 6-month change of -2.30% further confirms that the intermediate trend has rolled over, and the recent decline from the July high of $95.13 to the current $86.80 represents a roughly 8.8% pullback, suggesting momentum is decelerating and the market is repricing the stock's defensive premium.
Key technical support rests at the 52-week low of $74.55, while resistance is established at the 52-week high of $99.33; a breakdown below the $85 area (which has held as support in March and June 2026) could open the door to a retest of the $80 psychological level, while a breakout above $95 would signal renewed institutional accumulation. The stock's beta of 0.323 is remarkably low, indicating it is roughly 68% less volatile than the broader market — a defensive characteristic that appeals to risk-averse investors but also means the stock will likely underperform in strong bull markets. The maximum drawdown of -17.48% over the period reflects this low-volatility profile, and position sizing should account for the fact that CL is unlikely to deliver explosive upside but offers downside protection relative to high-beta names.
Beta
0.32
0.32x market volatility
Max Drawdown
-17.5%
Largest decline past year
52-Week Range
$75-$99
Price range past year
Annual Return
+5.5%
Cumulative gain past year
| Period | CL Return | S&P 500 |
|---|---|---|
| 1m | -4.4% | -2.0% |
| 3m | -3.1% | +1.4% |
| 6m | +0.4% | +15.0% |
| 1y | +5.5% | +15.7% |
| ytd | +13.1% | +11.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CL Fundamental Analysis
Colgate's revenue trajectory has shown a notable acceleration, with Q1 2026 revenue of $5.324 billion representing 8.41% year-over-year growth from Q1 2025's $4.911 billion, a meaningful step up from the roughly 1-3% growth seen in prior quarters. The sequential trend from Q2 2025 ($5.110 billion) through Q3 2025 ($5.131 billion) to Q4 2025 ($5.230 billion) and Q1 2026 ($5.324 billion) demonstrates consistent top-line expansion, with the most recent quarter marking the strongest sequential gain. Segment data shows Oral, Personal and Home Care contributing $4.034 billion and Pet Nutrition adding $1.196 billion, with the pet segment's premium positioning likely driving margin mix, though the company does not break out segment growth rates in the provided data. This acceleration, if sustained, could support a re-rating of the stock, but investors should note that the 8.4% growth rate may include pricing and currency tailwinds that could reverse.
Profitability remains robust, with Q1 2026 net income of $646 million on a 12.13% net margin, and gross margin of 60.59% — a level consistent with the company's historical range of 59-61% over the past eight quarters. However, the Q4 2025 quarter showed a net loss of $37 million (net margin of -0.71%) due to a $970 million other-expense charge, highlighting earnings volatility from non-operating items. Operating margin in Q1 2026 was 21.71%, down slightly from 22.20% in Q1 2025, suggesting modest margin compression, while the trailing twelve-month net margin of 10.46% and operating margin of 21.33% remain healthy for the household products industry. The company's gross margin stability above 60% is a testament to pricing power, but the slight year-over-year decline in operating margin warrants monitoring.
Colgate's balance sheet carries significant leverage, with a debt-to-equity ratio of 147.93% and a current ratio of 0.995, indicating that current liabilities slightly exceed current assets — a tight liquidity position. However, the company generates substantial free cash flow, with $3.767 billion in trailing twelve-month FCF and $609 million in Q1 2026 alone, providing ample coverage for its $417 million in quarterly dividends and $306 million in stock buybacks. The FCF yield of approximately 5.9% (based on $3.767 billion FCF and $63.9 billion market cap) is attractive for a defensive name, and the ROE of 39.48% reflects efficient capital deployment despite the high leverage. The dividend payout ratio of 85.5% is elevated, leaving limited room for dividend growth without earnings expansion, but the dividend yield of 2.85% remains a key attraction for income-oriented investors.
Quarterly Revenue
$5.3B
2026-03
Revenue YoY Growth
+8.4%
YoY Comparison
Gross Margin
60.6%
Latest Quarter
Free Cash Flow
$3.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CL Overvalued?
Because Colgate is profitable with positive net income, the PE ratio is the primary valuation metric. The stock trades at a trailing PE of 29.93x and a forward PE of 21.13x, with the gap between these two multiples implying the market expects significant earnings growth — approximately 41.6% — over the next twelve months, consistent with the analyst consensus EPS estimate of $4.79 versus trailing EPS of $0.033 (which appears distorted by one-time items). The forward PE of 21.13x is more representative of the company's earnings power, and the PEG ratio of -1.19 is not meaningful due to the trailing EPS distortion.
Compared to the broader Consumer Defensive sector, Colgate's forward PE of 21.13x represents a premium to the sector average, which typically ranges from 18-20x for large-cap staples. The PS ratio of 3.14x and EV/EBITDA of 17.85x are also above typical household products peers, though the premium is justified by Colgate's superior gross margin of 60.1% (versus the sector's typical 40-50%) and its leading global market share in oral care. The dividend yield of 2.85% is competitive with the sector, but the payout ratio of 85.5% is above the sector norm of 60-70%, suggesting less flexibility for future dividend increases.
Historically, Colgate's PE ratio has ranged from the low 20s to the low 30s over the past five years, with the current trailing PE of 29.93x near the upper end of that band, while the forward PE of 21.13x is closer to the middle. The PS ratio of 3.14x is near the lower end of its historical range (which has been as high as 16.9x in Q3 2024, though that was likely distorted by share count changes), suggesting the stock is not expensive on a sales basis. The current valuation appears to price in mid-single-digit revenue growth and modest margin expansion, leaving limited room for disappointment if the macro environment weakens or currency headwinds intensify.
PE
29.9x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 21x~32x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.8x
Enterprise Value Multiple
Investment Risk Disclosure
Colgate's financial risks are primarily balance-sheet related. The debt-to-equity ratio of 147.93% and current ratio of 0.995 indicate that current liabilities slightly exceed current assets, leaving a thin liquidity cushion. While trailing twelve-month free cash flow of $3.767 billion provides ample coverage for the $417 million quarterly dividend and $306 million in buybacks, the 85.5% payout ratio leaves little room for error if earnings decline. Additionally, the Q4 2025 net loss of $37 million due to a $970 million other-expense charge demonstrates how non-operating items can create significant earnings volatility, potentially undermining investor confidence.
Market and competitive risks are significant given Colgate's premium valuation and defensive positioning. The stock trades at a forward PE of 21.13x and EV/EBITDA of 17.85x, above the consumer defensive sector averages of 18-20x and 14-16x, respectively. With a beta of 0.323, the stock is less volatile than the market but also likely to underperform in strong bull markets, as evidenced by its 12.96 percentage point underperformance versus the S&P 500 over the past year. The recent news highlighting a rotation from growth to value stocks suggests that defensive names like Colgate may continue to face headwinds as investors favor more cyclical exposure. Furthermore, intense competition in oral care and pet nutrition, particularly from private-label brands and rivals like Procter & Gamble and Nestlé, could pressure market share and margins.
The worst-case scenario for Colgate would involve a combination of slowing revenue growth, margin compression, and a broader market rotation away from staples. If the Q1 2026 revenue acceleration proves unsustainable and currency headwinds intensify, the stock could retest its 52-week low of $74.55, representing a decline of approximately 14.1% from the current price of $86.80. In a more severe scenario where earnings disappoint and the multiple compresses to the low end of its historical range, the analyst low target of $87.00 offers little downside protection, but a break below $85 could open the door to the $80 psychological level and potentially the 52-week low. Given the maximum drawdown of -17.48% over the past period, investors could lose 15-20% from current levels in a prolonged adverse scenario.
FAQ
The key risks for CL are ranked as follows: 1) Financial risk: high debt-to-equity of 147.93% and a current ratio of 0.995 indicate tight liquidity and leverage, which could strain the balance sheet if earnings decline. 2) Valuation risk: the forward PE of 21.13x is above the sector average, and any slowdown in growth could trigger multiple compression. 3) Competitive risk: intense competition in oral care and pet nutrition from rivals like Procter & Gamble and Nestlé could pressure market share and margins. 4) Macro risk: with 70% of sales international and nearly half from emerging markets, currency fluctuations and geopolitical instability could significantly impact earnings. Additionally, the 85.5% payout ratio limits dividend growth flexibility.
Our 12-month forecast for CL includes three scenarios: a bull case with 25% probability targeting $98.95-$110.00, a base case with 55% probability targeting $87.00-$98.95, and a bear case with 20% probability targeting $74.55-$87.00. The base case is most likely, assuming revenue growth moderates to 4-6% and margins remain stable, leading the stock to trade toward the analyst average target of $98.95. The bull case requires sustained revenue acceleration above 6% and multiple expansion, while the bear case assumes growth stalls and the stock retests its 52-week low. The key assumption behind the base case is that Colgate maintains its pricing power and cost discipline, with no major currency or competitive shocks.
CL appears fairly valued to slightly overvalued. The forward PE of 21.13x is a premium to the consumer defensive sector average of 18-20x, and the EV/EBITDA of 17.85x is above the typical 14-16x range for household products peers. However, the premium is partially justified by Colgate's superior gross margin of 60.59% versus the sector's 40-50% and its leading global market share in oral care. The PS ratio of 3.14x is near the lower end of its historical range, suggesting the stock is not expensive on a sales basis. The market is pricing in mid-single-digit revenue growth and modest margin expansion, leaving little room for disappointment. If growth accelerates, the multiple could expand toward the high end of its historical range, but if growth stalls, the stock could de-rate toward 18x forward earnings, implying a price near $86.
CL is a good buy for income-focused investors seeking stability and a reliable dividend, but it may not appeal to those seeking high growth. The stock offers a 2.85% dividend yield and trades at a forward PE of 21.13x, with analyst consensus implying 14% upside to the average target of $98.95. However, the high payout ratio of 85.5% and premium valuation relative to the sector (18-20x forward PE) suggest limited margin of safety. The biggest downside risk is a retest of the 52-week low of $74.55, which would represent a 14% decline from current levels. For long-term investors comfortable with low volatility (beta 0.323), CL can serve as a core defensive holding, but it is not a compelling buy at current levels without a pullback toward $80-82.
CL is best suited for long-term investment, with a suggested minimum holding period of 3-5 years. The stock's low beta of 0.323 and defensive characteristics make it ideal for income-focused investors seeking stable dividends and capital preservation. The 2.85% dividend yield and consistent free cash flow generation provide a reliable income stream, but the premium valuation and modest growth prospects limit short-term upside. Short-term trading is not recommended due to the stock's low volatility and range-bound technical pattern, with the price currently at $86.80, roughly mid-way between the 52-week low of $74.55 and high of $99.33. Long-term investors can benefit from dividend reinvestment and potential multiple expansion if growth accelerates, but should be prepared for underperformance in strong bull markets.
